- Home
- IPGP vs MRUS Comparison
IPGP vs MRUS Comparison
Compare IPGP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPGP
- MRUS
- Stock Information
- Founded
- IPGP 1990
- MRUS 2003
- Country
- IPGP United States
- MRUS Netherlands
- Employees
- IPGP N/A
- MRUS N/A
- Industry
- IPGP Semiconductors
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- IPGP Technology
- MRUS Health Care
- Exchange
- IPGP Nasdaq
- MRUS Nasdaq
- Market Cap
- IPGP 3.3B
- MRUS 2.7B
- IPO Year
- IPGP 2006
- MRUS 2016
- Fundamental
- Price
- IPGP $60.15
- MRUS $40.90
- Analyst Decision
- IPGP Buy
- MRUS Strong Buy
- Analyst Count
- IPGP 7
- MRUS 14
- Target Price
- IPGP $72.75
- MRUS $87.00
- AVG Volume (30 Days)
- IPGP 350.5K
- MRUS 770.0K
- Earning Date
- IPGP 05-06-2025
- MRUS 05-07-2025
- Dividend Yield
- IPGP N/A
- MRUS N/A
- EPS Growth
- IPGP N/A
- MRUS N/A
- EPS
- IPGP N/A
- MRUS N/A
- Revenue
- IPGP $952,918,000.00
- MRUS $54,732,000.00
- Revenue This Year
- IPGP $2.05
- MRUS $26.81
- Revenue Next Year
- IPGP $7.00
- MRUS $23.85
- P/E Ratio
- IPGP N/A
- MRUS N/A
- Revenue Growth
- IPGP N/A
- MRUS 42.77
- 52 Week Low
- IPGP $48.59
- MRUS $33.19
- 52 Week High
- IPGP $92.21
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- IPGP 53.02
- MRUS 45.06
- Support Level
- IPGP $51.77
- MRUS $37.92
- Resistance Level
- IPGP $64.58
- MRUS $46.36
- Average True Range (ATR)
- IPGP 2.49
- MRUS 2.58
- MACD
- IPGP 0.44
- MRUS -0.27
- Stochastic Oscillator
- IPGP 65.42
- MRUS 35.31
About IPGP IPG Photonics Corporation
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, fiber amplifiers, and diode lasers, which are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. A large majority of the firm's revenue is derived from materials processing applications for fiber lasers, including cutting and welding, marking and engraving, and micro-processing. The company generates a majority of its revenue from China and also has its presence in North America, Japan, Germany, and other markets.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.